Molecular Subtypes, microRNAs and Immunotherapy Response in Metastatic Colorectal Cancer
Medicina · 2024
DOI: 10.3390/medicina60030397 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicina, 2024. Verfasst von Alexandra Gherman und 7 weiteren Autor:innen. Beteiligte Einrichtung: 10th Department of Medical Oncology, University of Medicine and Pharmacy "Iuliu Hatieganu", 8 Victor Babes Street, 400012 Cluj-Napoca, Romania. Hauptthemen laut MEDLINE: MicroRNAs, Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Iuliu Hațieganu University of Medicine and Pharmacy, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Abstract (Originalsprache)
Currently, only a limited set of molecular traits are utilized to direct treatment for metastatic CRC (mCRC). The molecular classification of CRC depicts tumor heterogeneity based on gene expression patterns and aids in comprehending the biological characteristics of tumor formation, growth and prognosis. Additionally, it assists physicians in tailoring the therapeutic approach. Microsatellite instability (MSI-H)/deficient mismatch repair proteins (MMRd) status has become a ubiquitous biomarker in solid tumors, caused by mutations or methylation of genes and, in turn, the accumulation of mutations and antigens that subsequently induce an immune response. Immune checkpoint inhibitors (ICI) have recently received approval for the treatment of mCRC with MSI-H/MMRd status. However, certain individuals experience either initial or acquired resistance. The tumor-programmed cell death ligand 1 (PD-L1) has been linked to the ability of CRC to evade the immune system and promote its growth. Through comprehensive research conducted via the PUBMED database, the objectives of this paper were to review the molecular characteristics linked to tumor response in metastatic CRC in light of improved patients’ outcomes following ICI therapies as seen in clinical trials and to identify particular microRNAs that can modulate the expression of specific oncoproteins, such as PD-L1, and disrupt the mechanisms that allow the immune system to be evaded.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 10th Department of Medical Oncology, University of Medicine and Pharmacy "Iuliu Hatieganu", 8 Victor Babes Street, 400012 Cluj-Napoca, Romania.
- Department of Medical Oncology, The Oncology Institute "Prof. Dr. Ion Chiricuta", 34-36 Republicii Street, 400015 Cluj-Napoca, Romania.
- Department of Genetics, Genomics and Experimental Pathology, The Oncology Institute "Prof. Dr. Ion Chiricuta", 400015 Cluj-Napoca, Romania.
- 10th Department of Radiation Oncology, University of Medicine and Pharmacy "Iuliu Hatieganu", 8 Victor Babes Street, 400012 Cluj-Napoca, Romania.
- Department of Radiation Oncology, The Oncology Institute "Prof. Dr. Ion Chiricuta", 34-36 Republicii Street, 400015 Cluj-Napoca, Romania.
- Department of Anatomy, Faculty of Medicine, Ovidius University, 124 Mamaia Boulevard, 900527 Constanta, Romania.
ORCID-Profile: Alexandra Gherman, Ovidiu Balacescu
Förderung
- Iuliu Hațieganu University of Medicine and Pharmacy
- “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
Zitieren
APA
Gherman, A., Bolundut, D., Ecea, R., Balacescu, L., Curcean, S., Dina, C., Balacescu, O., & Cainap, C. (2024). Molecular Subtypes, microRNAs and Immunotherapy Response in Metastatic Colorectal Cancer. Medicina. https://doi.org/10.3390/medicina60030397
Vancouver
Gherman A, Bolundut D, Ecea R, Balacescu L, Curcean S, Dina C, et al. Molecular Subtypes, microRNAs and Immunotherapy Response in Metastatic Colorectal Cancer. Medicina. 2024. doi:10.3390/medicina60030397
BibTeX
@article{Gherman2024,
author = {Gherman, Alexandra and Bolundut, Dinu and Ecea, Radu and Balacescu, Loredana and Curcean, Sebastian and Dina, Constantin and Balacescu, Ovidiu and Cainap, Calin},
title = {Molecular Subtypes, microRNAs and Immunotherapy Response in Metastatic Colorectal Cancer},
journal = {Medicina},
year = {2024},
doi = {10.3390/medicina60030397}
}
EUVIMED